MONROE TOWNSHIP, N.J.--(BUSINESS WIRE)--Bracco Imaging, through its business unit Bracco Injeneering SA, announced today the availability of its EmpowerCTA+, an advanced engineering contrast injection system that puts the radiologic technologist in control, in the computed tomography suite.
The EmpowerCTA+ has initially been launched in the United States then gradually in Europe, and it will be presented at the upcoming European Congress of Radiology (ECR, Vienna, 4-8 March 2015).
The EmpowerCTA+ contrast injection system has been reengineered, setting a new standard in the contrast power injectors market. The system was designed to streamline workflow, with enhanced safety and control at the patient side.
Bracco’s EmpowerCTA+ was reengineered with an intuitive and intelligent design with technological enhancements, in tune with the needs of patients, radiologic technologists and the healthcare marketplace. Its advanced touchscreen technology enables technologists to customize the contrast injection experience right at the patient’s side with new enhancements, including real time variable flow rates, saline advance, and saline jump.
“We are extremely pleased to announce the availability on the market of the EmpowerCTA+,“ said Vittorio Puppo, Head of Business Unit Injectors and President & CEO at Bracco Diagnostics Inc. “The contrast injector system was reengineered with digital touch technology and a new visionary design with high performance, which will help us to increase market penetration.”
EmpowerCTA+ has a saline advance function which tests a patient’s patency and vein integrity while its saline jump feature minimizes the amount of contrast a patient receives. The injector’s unique patented EDA™ (extravasation detection accessory) advances patient care while providing additional safety and peace of mind for the technologist. In addition, its eGFR calculator simplifies calculations for kidney evaluation function prior to contrast delivery. The risk of air embolisms to the patient is reduced due to the system’s built-in tilt sensor and lock. Technologists have greater control with the touchscreen technology at the patient’s side.
The EmpowerCTA+ Injector System is intended for the vascular administration of contrast and flushing media. The injector system is used in conjunction with computed tomography scanning of the body with an optional interface to a CT scanner and an optional calculator for glomerular filtration rate.
The Extravasation Detection Accessory is an optional accessory and is indicated for the detection of extravasations of ionic and nonionic contrast during CT procedures using a power injector.
The EmpowerCTA+ Injector System is not intended for use as a long-term infusion pump, nor is it intended to be used to inject any agents other than contrast media or flushing media. Do not attempt to use the injector for any other purpose (such as chemotherapy or drug infusion). The EmpowerCTA+ Injection System should not be used to inject substances into nonvascular body cavities. Any applications of the EmpowerCTA+ Injection System other than those described in the User’s Guide are inappropriate and should not be attempted.
Complete instructions for use available upon request.
Not all products available in all global markets.
Protocols have been independently developed and are not intended as medical advice. Bracco and Bracco Injeneering SA shall not be responsible for any physicians’ reliance on these or any other products.
About Bracco Injeneering SA
A Business Unit of Bracco Imaging since 2012, based in Lausanne (Switzerland), Bracco Injeneering specializes in developing the best-in-class integrated injection solutions with a strong heritage in research and innovation. It provides quality solutions for state-of-the-art radiology centers, offering proven injection technology, built on Bracco Imaging expertise. Thanks to this strengthened products portfolio including CT Exprès™, EmpowerCTA®+, EmpowerMR®, Nexo® and NexoDose® Bracco Imaging will be able to focus on constant innovation not only for devices but also for software development and data management.
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.
Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), Nuclear Medicine through radioactive tracers, and Gastrointestinal Endoscopy. The diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.
The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe and Japan operating through the Joint Venture Bracco-Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.
Operational investments have been made in order to achieve top quality, compliant and sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.
Bracco Imaging is an innovative Research and Development (R&D) structure with an efficient process oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centres located in Italy, Switzerland, and USA.
To learn more about Bracco Imaging, visit www.braccoimaging.com.
All trademarks are the property of their respective owners.